Kinase Inhibitors Market Analysis
With the advantage of oral availability and the speedy onset of action, kinase inhibitors have shown the potential to be the game-changer in the management of autoimmune diseases. As per the DelveInsight, the kinase inhibitors market size is likely to escalate as there is a plenitude of drugs in the pipeline which are being evaluated for various indications.
Some of the emerging therapies include Ritlecitinib, Ritlecitinib/PF-06650833/ Tofacitinib, Abrocitinib, PF-06826647, Brepocitinib, SHR0302, Ruxolitinib, Branebrutinib, Deucravecitinib, Belumosudil, ATI-450, Remibrutinib and Izencitinib. The launch of the emerging therapies during the forecast is expected to increase the market share for the Kinase Inhibitors owing to their high costs. Some of the key kinase inhibitors companies operating in the market include Pfizer, Reinstone Biopharma, Incyte, Bristol Myers Squibb, Kadmon, Aclaris Therapeutics, Inc., Novartis, Theravance Biopharma US, and many others.
For more details, visit: Kinase Inhibitors Market Analysis